Pluripotent stem cells are cells that have the capacity to self-renew by dividing and to develop into the three primary germ cell layers of the early embryo and therefore into all cells of the ...

Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- ...

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the ...

ALLO-316, a CD70-targeting CAR T-cell therapy, has demonstrated activity in patients with previously treated, advanced ccRCC.

Title: Comprehensive biomarker analyses from a Phase 1 study reveals marked tumor microenvironment modulation in patients with advanced solid tumors treated with MP0317, a FAP-localized CD40 agonistic ...

Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit attended the 5th RAS Initiative Symposium, hearing about ...

Experimental Transplantation: Basic and Translational: Poster III The full abstracts will be available on the ASH website from 9:00 am ET on November 5, 2024. About MP0533 (CD33 x CD123 x CD70 x CD3) ...

Basel, 05 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) An ...

Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease ...

Outpace Bio, a cell therapy company using unrivaled AI-powered protein design to program immune cells with improved efficacy against solid tumors, announced today that it will present new data on its ...